After Cantor Fitzgerald and H.C. Wainwright gave Strongbridge Biopharma Plc (NASDAQ: SBBP) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Hartaj Singh maintained a Buy rating on Strongbridge Biopharma Plc yesterday. The company’s shares closed yesterday at $5.59.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 3.3% and a 48.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Actinium Pharmaceuticals, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Strongbridge Biopharma Plc is a Strong Buy with an average price target of $14.50, a 159.4% upside from current levels. In a report issued on March 11, Laidlaw also maintained a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
Based on Strongbridge Biopharma Plc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $84.06 million. In comparison, last year the company had a GAAP net loss of $18.75 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBBP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.
